JP4238131B2 - 非シアノアクリレートレオロジー改良剤を有する塞栓用組成物 - Google Patents
非シアノアクリレートレオロジー改良剤を有する塞栓用組成物 Download PDFInfo
- Publication number
- JP4238131B2 JP4238131B2 JP2003521688A JP2003521688A JP4238131B2 JP 4238131 B2 JP4238131 B2 JP 4238131B2 JP 2003521688 A JP2003521688 A JP 2003521688A JP 2003521688 A JP2003521688 A JP 2003521688A JP 4238131 B2 JP4238131 B2 JP 4238131B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- poly
- composition according
- cyanoacrylate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 176
- 229920001651 Cyanoacrylate Polymers 0.000 title claims abstract description 68
- 239000006254 rheological additive Substances 0.000 title claims description 31
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 title claims description 28
- 230000010102 embolization Effects 0.000 title abstract description 3
- -1 alkyl cyanoacrylate Chemical compound 0.000 claims abstract description 60
- 239000000463 material Substances 0.000 claims abstract description 56
- 239000000178 monomer Substances 0.000 claims abstract description 42
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 35
- 239000004014 plasticizer Substances 0.000 claims abstract description 31
- 239000003381 stabilizer Substances 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims description 46
- 239000007787 solid Substances 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000003921 oil Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000011236 particulate material Substances 0.000 claims description 7
- 150000003254 radicals Chemical class 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 229910052737 gold Inorganic materials 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 150000002895 organic esters Chemical class 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 150000001993 dienes Chemical class 0.000 claims description 3
- 150000007522 mineralic acids Chemical group 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 229910052715 tantalum Inorganic materials 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 2
- GEIAQOFPUVMAGM-UHFFFAOYSA-N ZrO Inorganic materials [Zr]=O GEIAQOFPUVMAGM-UHFFFAOYSA-N 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 claims description 2
- 230000009477 glass transition Effects 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229920001567 vinyl ester resin Polymers 0.000 claims description 2
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 229910004158 TaO Inorganic materials 0.000 claims 1
- 229940036358 bismuth subcarbonate Drugs 0.000 claims 1
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical group CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 229910052726 zirconium Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 238000000518 rheometry Methods 0.000 abstract description 7
- 230000005856 abnormality Effects 0.000 abstract description 3
- 210000005166 vasculature Anatomy 0.000 abstract 1
- 230000003073 embolic effect Effects 0.000 description 37
- 239000007788 liquid Substances 0.000 description 22
- 239000002245 particle Substances 0.000 description 22
- 206010002329 Aneurysm Diseases 0.000 description 14
- 238000006116 polymerization reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 230000006496 vascular abnormality Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000005744 arteriovenous malformation Effects 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 206010016717 Fistula Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000003890 fistula Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007972 injectable composition Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 201000008450 Intracranial aneurysm Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 125000005233 alkylalcohol group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009974 thixotropic effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000004830 Super Glue Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 2
- 229950010048 enbucrilate Drugs 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- IFPMZBBHBZQTOV-UHFFFAOYSA-N 1,3,5-trinitro-2-(2,4,6-trinitrophenyl)-4-[2,4,6-trinitro-3-(2,4,6-trinitrophenyl)phenyl]benzene Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C=2C(=C(C=3C(=CC(=CC=3[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)C(=CC=2[N+]([O-])=O)[N+]([O-])=O)[N+]([O-])=O)=C1[N+]([O-])=O IFPMZBBHBZQTOV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- AUYFHLCJKFSVOG-UHFFFAOYSA-N benzene-1,4-diol;phosphoric acid Chemical compound OP(O)(O)=O.OC1=CC=C(O)C=C1 AUYFHLCJKFSVOG-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- QNVRIHYSUZMSGM-UHFFFAOYSA-N hexan-2-ol Chemical compound CCCCC(C)O QNVRIHYSUZMSGM-UHFFFAOYSA-N 0.000 description 1
- RKVIEVIJBJXOFV-UHFFFAOYSA-N hexan-2-yl 2-cyanoprop-2-enoate Chemical compound CCCCC(C)OC(=O)C(=C)C#N RKVIEVIJBJXOFV-UHFFFAOYSA-N 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- LAYLQVBQIBQVLL-UHFFFAOYSA-N iofendylate Chemical compound CCOC(=O)CCCCCCCCC(C)C1=CC=C(I)C=C1 LAYLQVBQIBQVLL-UHFFFAOYSA-N 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000002794 monomerizing effect Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- JMOHEPRYPIIZQU-UHFFFAOYSA-N oxygen(2-);tantalum(2+) Chemical compound [O-2].[Ta+2] JMOHEPRYPIIZQU-UHFFFAOYSA-N 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F20/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F20/02—Monocarboxylic acids having less than ten carbon atoms, Derivatives thereof
- C08F20/10—Esters
- C08F20/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F20/32—Esters containing oxygen in addition to the carboxy oxygen containing epoxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Materials For Medical Uses (AREA)
- Polymerisation Methods In General (AREA)
- Graft Or Block Polymers (AREA)
- Dental Preparations (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Surgical Instruments (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/933,316 US7687053B2 (en) | 2001-08-20 | 2001-08-20 | Embolic compositions with non-cyanoacrylate rheology modifying agents |
| PCT/US2002/021532 WO2003016364A1 (en) | 2001-08-20 | 2002-07-09 | Embolic compositions with non-cyanoacrylate rheology modifying agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008288650A Division JP2009072610A (ja) | 2001-08-20 | 2008-11-11 | 非シアノアクリレートレオロジー改良剤を有する塞栓用組成物の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500414A JP2005500414A (ja) | 2005-01-06 |
| JP2005500414A5 JP2005500414A5 (enExample) | 2006-01-05 |
| JP4238131B2 true JP4238131B2 (ja) | 2009-03-11 |
Family
ID=25463727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003521688A Expired - Lifetime JP4238131B2 (ja) | 2001-08-20 | 2002-07-09 | 非シアノアクリレートレオロジー改良剤を有する塞栓用組成物 |
| JP2008288650A Pending JP2009072610A (ja) | 2001-08-20 | 2008-11-11 | 非シアノアクリレートレオロジー改良剤を有する塞栓用組成物の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008288650A Pending JP2009072610A (ja) | 2001-08-20 | 2008-11-11 | 非シアノアクリレートレオロジー改良剤を有する塞栓用組成物の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7687053B2 (enExample) |
| EP (1) | EP1425319B1 (enExample) |
| JP (2) | JP4238131B2 (enExample) |
| AT (1) | ATE374219T1 (enExample) |
| CA (1) | CA2452505A1 (enExample) |
| DE (1) | DE60222680T2 (enExample) |
| WO (1) | WO2003016364A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032853A1 (en) * | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| ATE502657T1 (de) * | 2001-05-01 | 2011-04-15 | Av Topchiev Inst Petrochemical | Zweiphasige, wasserabsorbierende bioadhäsive zusammenstezung |
| US7687053B2 (en) * | 2001-08-20 | 2010-03-30 | Boston Scientific Scimed, Inc. | Embolic compositions with non-cyanoacrylate rheology modifying agents |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7131997B2 (en) | 2002-03-29 | 2006-11-07 | Scimed Life Systems, Inc. | Tissue treatment |
| US7094369B2 (en) | 2002-03-29 | 2006-08-22 | Scimed Life Systems, Inc. | Processes for manufacturing polymeric microspheres |
| US7053134B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Forming a chemically cross-linked particle of a desired shape and diameter |
| US7459142B2 (en) * | 2002-06-06 | 2008-12-02 | Micro Therapeutics, Inc. | High viscosity embolizing compositions comprising prepolymers |
| US8425549B2 (en) | 2002-07-23 | 2013-04-23 | Reverse Medical Corporation | Systems and methods for removing obstructive matter from body lumens and treating vascular defects |
| US7449236B2 (en) | 2002-08-09 | 2008-11-11 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US7588825B2 (en) | 2002-10-23 | 2009-09-15 | Boston Scientific Scimed, Inc. | Embolic compositions |
| WO2004075989A1 (en) * | 2003-02-26 | 2004-09-10 | Micro Therapeutics Inc. | Fumed silica embolic compositions |
| US20050025707A1 (en) * | 2003-02-27 | 2005-02-03 | Patterson William R. | Fumed silica embolic compositions |
| WO2005067990A1 (en) * | 2004-01-07 | 2005-07-28 | Boston Scientific Santa Rosa Corporation | Methods, compositions, and devices for embolizing body lumens |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| EP1750619B1 (en) | 2004-05-25 | 2013-07-24 | Covidien LP | Flexible vascular occluding device |
| EP2419048A4 (en) | 2004-05-25 | 2014-04-09 | Covidien Lp | VACCINE PLANTATION FOR ANEURYSMA |
| US9675476B2 (en) | 2004-05-25 | 2017-06-13 | Covidien Lp | Vascular stenting for aneurysms |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| US20070078207A1 (en) * | 2005-09-30 | 2007-04-05 | Jonn Jerry Y | Stabilizer cyanoacrylate formulations |
| US7501179B2 (en) | 2005-12-21 | 2009-03-10 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US20070184087A1 (en) * | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
| WO2007100556A1 (en) | 2006-02-22 | 2007-09-07 | Ev3 Inc. | Embolic protection systems having radiopaque filter mesh |
| CA2652753C (en) * | 2006-05-12 | 2015-12-08 | Cordis Corporation | Balloon expandable bioabsorbable drug eluting stent |
| AU2007249229B2 (en) * | 2006-05-12 | 2013-05-23 | Cardinal Health 529, Llc | Balloon expandable bioabsorbable drug eluting flexible stent |
| KR20100106966A (ko) * | 2007-11-12 | 2010-10-04 | 밸러 메디컬, 인코포레이티드 | 의료용 시아노아크릴레이트의 단일 바이알 제형 |
| US7972373B2 (en) * | 2007-12-19 | 2011-07-05 | Advanced Technologies And Regenerative Medicine, Llc | Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts |
| ES2430117T3 (es) | 2008-04-21 | 2013-11-19 | Covidien Lp | Dispositivos embólicos de bola de trenza y sistemas de colocación |
| WO2009140437A1 (en) | 2008-05-13 | 2009-11-19 | Nfocus Neuromedical, Inc. | Braid implant delivery systems |
| US10143455B2 (en) | 2011-07-20 | 2018-12-04 | Covidien LLP | Enhanced ultrasound visualization of intravascular devices |
| CN105212984B (zh) | 2009-02-20 | 2017-12-22 | 柯惠有限合伙公司 | 用于治疗静脉机能不全的静脉闭塞的方法和装置 |
| US8409269B2 (en) | 2009-12-21 | 2013-04-02 | Covidien Lp | Procedures for vascular occlusion |
| US8998947B2 (en) | 2010-09-10 | 2015-04-07 | Medina Medical, Inc. | Devices and methods for the treatment of vascular defects |
| EP2613735B1 (en) | 2010-09-10 | 2018-05-09 | Covidien LP | Devices for the treatment of vascular defects |
| WO2012078678A1 (en) | 2010-12-06 | 2012-06-14 | Tyco Healthcare Group Lp | Vascular remodeling device |
| US9089332B2 (en) | 2011-03-25 | 2015-07-28 | Covidien Lp | Vascular remodeling device |
| US10196543B2 (en) | 2011-03-31 | 2019-02-05 | Adhezion Biomedical, Llc | Fast bonding hair/eyelash extension adhesive compositions based on medical grade high viscosity cyanoacrylates |
| AU2012253583B2 (en) | 2011-05-11 | 2014-09-25 | Covidien Lp | Vascular remodeling device |
| US9060886B2 (en) | 2011-09-29 | 2015-06-23 | Covidien Lp | Vascular remodeling device |
| US9072620B2 (en) | 2011-11-04 | 2015-07-07 | Covidien Lp | Protuberant aneurysm bridging device deployment method |
| US9011480B2 (en) | 2012-01-20 | 2015-04-21 | Covidien Lp | Aneurysm treatment coils |
| US8808620B1 (en) | 2012-02-22 | 2014-08-19 | Sapheon, Inc. | Sterilization process design for a medical adhesive |
| US9452070B2 (en) | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
| CN108354645A (zh) | 2012-11-13 | 2018-08-03 | 柯惠有限合伙公司 | 封堵装置 |
| WO2014145012A2 (en) | 2013-03-15 | 2014-09-18 | Covidien Lp | Delivery and detachment mechanisms for vascular implants |
| CN105142545B (zh) | 2013-03-15 | 2018-04-06 | 柯惠有限合伙公司 | 闭塞装置 |
| US9795400B2 (en) | 2013-11-13 | 2017-10-24 | Covidien Lp | Galvanically assisted attachment of medical devices to thrombus |
| CA2935959A1 (en) * | 2014-01-07 | 2015-07-16 | Covidien Lp | Cyanoacrylate compositions including non-agglomerating radiopaque nanoparticles |
| EP3129077A4 (en) * | 2014-04-11 | 2017-11-22 | Covidien LP | Tagged surgical instruments and methods therefor |
| US9713475B2 (en) | 2014-04-18 | 2017-07-25 | Covidien Lp | Embolic medical devices |
| US9814466B2 (en) | 2014-08-08 | 2017-11-14 | Covidien Lp | Electrolytic and mechanical detachment for implant delivery systems |
| US10478194B2 (en) | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
| US10314593B2 (en) | 2015-09-23 | 2019-06-11 | Covidien Lp | Occlusive devices |
| US10893869B2 (en) | 2016-03-24 | 2021-01-19 | Covidien Lp | Thin wall constructions for vascular flow diversion |
| US10828039B2 (en) | 2016-06-27 | 2020-11-10 | Covidien Lp | Electrolytic detachment for implantable devices |
| US10828037B2 (en) | 2016-06-27 | 2020-11-10 | Covidien Lp | Electrolytic detachment with fluid electrical connection |
| US11051822B2 (en) | 2016-06-28 | 2021-07-06 | Covidien Lp | Implant detachment with thermal activation |
| US10478195B2 (en) | 2016-08-04 | 2019-11-19 | Covidien Lp | Devices, systems, and methods for the treatment of vascular defects |
| US10576099B2 (en) | 2016-10-21 | 2020-03-03 | Covidien Lp | Injectable scaffold for treatment of intracranial aneurysms and related technology |
| US10675036B2 (en) | 2017-08-22 | 2020-06-09 | Covidien Lp | Devices, systems, and methods for the treatment of vascular defects |
| US11065136B2 (en) | 2018-02-08 | 2021-07-20 | Covidien Lp | Vascular expandable devices |
| US11065009B2 (en) | 2018-02-08 | 2021-07-20 | Covidien Lp | Vascular expandable devices |
| US10912569B2 (en) | 2018-08-22 | 2021-02-09 | Covidien Lp | Aneurysm treatment coils and associated systems and methods of use |
| US10905432B2 (en) | 2018-08-22 | 2021-02-02 | Covidien Lp | Aneurysm treatment coils and associated systems and methods of use |
| US11730485B2 (en) | 2018-12-17 | 2023-08-22 | Covidien Lp | Devices, systems, and methods for the treatment of vascular defects |
| EP4054440B1 (en) | 2019-11-04 | 2024-06-05 | Covidien LP | Manufacturing method of devices for treatment of intracranial aneurysms |
| US11931041B2 (en) | 2020-05-12 | 2024-03-19 | Covidien Lp | Devices, systems, and methods for the treatment of vascular defects |
| CN112870428B (zh) * | 2021-01-21 | 2022-05-27 | 北京冠合医疗科技有限公司 | 一种显影清晰的栓塞材料及其制备方法 |
| US12364793B2 (en) | 2021-03-16 | 2025-07-22 | Covidien Lp | Injectable biopolymer compositions and associated systems and methods |
| CN115364272B (zh) * | 2022-09-09 | 2023-08-08 | 江西博恩锐尔生物科技有限公司 | 柔软度可调的血管栓塞剂及其制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL277423A (enExample) | 1961-04-20 | |||
| US3896077A (en) * | 1966-10-10 | 1975-07-22 | Fred Leonard | Underwater adhesive |
| US3728375A (en) | 1971-05-12 | 1973-04-17 | Eastman Kodak Co | Cyanoacrylate adhesive compositions |
| US4406878A (en) * | 1978-08-02 | 1983-09-27 | Eastman Kodak Company | Iodinated contrast agent for radiography |
| DE2850918A1 (de) * | 1978-11-24 | 1980-06-04 | Bayer Ag | Roentgenopake dentalwerkstoffe auf basis von organischen kunststoffen in pastoeser form |
| IL63876A0 (en) | 1980-10-20 | 1981-12-31 | Population Res Inc | Radiopaque cyanoacrylates |
| US4713235A (en) | 1981-05-26 | 1987-12-15 | Crx Medical, Inc. | Radiopaque cyanoacrylates |
| CA1225585A (en) * | 1983-06-30 | 1987-08-18 | Maria T. Litvinova | Composition for embolization of blood vessels |
| US5322499A (en) | 1985-09-20 | 1994-06-21 | Liprie Sam F | Continuous sheated low dose radioactive core adapted for cutting into short sealed segments |
| GB8729140D0 (en) | 1987-12-14 | 1988-01-27 | Lingner & Fischer Gmbh | Adhesive |
| US5326552A (en) * | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
| DE59409568D1 (de) | 1993-09-09 | 2000-11-30 | Schering Ag | Wirkstoffe und gas enthaltende mikropartikel |
| US5795331A (en) | 1994-01-24 | 1998-08-18 | Micro Therapeutics, Inc. | Balloon catheter for occluding aneurysms of branch vessels |
| DE69503844T2 (de) | 1994-06-08 | 1999-04-22 | Taoka Chemical Co., Ltd., Osaka | Klebemittelzusammensetzung auf Alphacyanoacrylat Basis |
| US5739205A (en) | 1994-06-08 | 1998-04-14 | Taoka Chemical Company, Limited | α-cyanoacrylate adhesive composition |
| JPH08259899A (ja) * | 1995-03-23 | 1996-10-08 | Three Bond Co Ltd | シアノアクリレート系接着剤組成物 |
| US5795922A (en) * | 1995-06-06 | 1998-08-18 | Clemson University | Bone cement composistion containing microencapsulated radiopacifier and method of making same |
| US5591195A (en) | 1995-10-30 | 1997-01-07 | Taheri; Syde | Apparatus and method for engrafting a blood vessel |
| US5882334A (en) | 1995-12-04 | 1999-03-16 | Target Therapeutics, Inc. | Balloon/delivery catheter assembly with adjustable balloon positioning |
| US5702361A (en) | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
| US5817343A (en) | 1996-05-14 | 1998-10-06 | Alkermes, Inc. | Method for fabricating polymer-based controlled-release devices |
| JP2001509133A (ja) * | 1996-05-31 | 2001-07-10 | マイクロ セラピューティクス インコーポレーテッド | 閉塞化血管における使用のための組成物 |
| US5925683A (en) * | 1996-10-17 | 1999-07-20 | Target Therapeutics, Inc. | Liquid embolic agents |
| US6020004A (en) | 1997-04-17 | 2000-02-01 | Amgen Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
| US6538026B1 (en) * | 1997-09-11 | 2003-03-25 | Provasis Therapeutics, Inc. | Compositions useful for remodeling body spaces |
| US6476069B2 (en) | 1997-09-11 | 2002-11-05 | Provasis Therapeutics Inc. | Compositions for creating embolic agents and uses thereof |
| US6037366A (en) * | 1997-09-11 | 2000-03-14 | Prohold Medical Technologies, Inc. | Composition for creating vascular occlusions |
| US6476070B2 (en) * | 1997-09-11 | 2002-11-05 | Provasis Therapeutics Inc. | Compositions useful for remodeling body spaces |
| US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
| US6015424A (en) | 1998-04-28 | 2000-01-18 | Microvention, Inc. | Apparatus and method for vascular embolization |
| US6203779B1 (en) * | 1999-03-19 | 2001-03-20 | Charlie Ricci | Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms |
| US7687053B2 (en) * | 2001-08-20 | 2010-03-30 | Boston Scientific Scimed, Inc. | Embolic compositions with non-cyanoacrylate rheology modifying agents |
-
2001
- 2001-08-20 US US09/933,316 patent/US7687053B2/en not_active Expired - Lifetime
-
2002
- 2002-07-09 WO PCT/US2002/021532 patent/WO2003016364A1/en not_active Ceased
- 2002-07-09 AT AT02746922T patent/ATE374219T1/de not_active IP Right Cessation
- 2002-07-09 DE DE60222680T patent/DE60222680T2/de not_active Expired - Lifetime
- 2002-07-09 EP EP02746922A patent/EP1425319B1/en not_active Expired - Lifetime
- 2002-07-09 CA CA002452505A patent/CA2452505A1/en not_active Abandoned
- 2002-07-09 JP JP2003521688A patent/JP4238131B2/ja not_active Expired - Lifetime
-
2008
- 2008-11-11 JP JP2008288650A patent/JP2009072610A/ja active Pending
-
2010
- 2010-02-17 US US12/707,373 patent/US20100144895A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2452505A1 (en) | 2003-02-27 |
| US7687053B2 (en) | 2010-03-30 |
| EP1425319A1 (en) | 2004-06-09 |
| ATE374219T1 (de) | 2007-10-15 |
| EP1425319B1 (en) | 2007-09-26 |
| US20030039696A1 (en) | 2003-02-27 |
| JP2005500414A (ja) | 2005-01-06 |
| WO2003016364A1 (en) | 2003-02-27 |
| DE60222680D1 (de) | 2007-11-08 |
| US20100144895A1 (en) | 2010-06-10 |
| JP2009072610A (ja) | 2009-04-09 |
| DE60222680T2 (de) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4238131B2 (ja) | 非シアノアクリレートレオロジー改良剤を有する塞栓用組成物 | |
| JP6710746B2 (ja) | ポリマー治療組成物 | |
| CA2481365C (en) | Occlusive composition comprising a poly (2-cyanoacrylate) monomer | |
| AU778078B2 (en) | Cyanoacrylates comprising inhibitors and an opacifying agent as adhesives | |
| US20040197302A1 (en) | Prepolymeric materials for site specific delivery to the body | |
| JP2003534406A (ja) | 重合可能な組成物および使用法 | |
| US20050287216A1 (en) | Medical imaging agents for injectable compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20041025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050630 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20071116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071204 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080229 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080403 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080513 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080811 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080821 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081111 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081209 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4238131 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111226 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111226 Year of fee payment: 3 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111226 Year of fee payment: 3 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111226 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121226 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121226 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131226 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |